Shionogi’s influenza drug S-033188 achieves main endpoint in global phase III

The endonuclease inhibitor (Peramivir, a neuraminidase inhibitor) shortened disease duration of influenza patients lowering the virus titer superior to Tamiflu

Shionogi press release, July 25, 2017

Most popular posts: